Brought to you by:
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy over bypass
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD) heavyweights against one another yielded an audience vote that went against the motion, “Bypass surgery is…
Shape Memory Medical announces first patient treated in the AAA-SHAPE randomised controlled pivotal trial
Shape Memory Medical recently announced that the first patient has been treated in the AAA-SHAPE pivotal trial. AAA-SHAPE (Abdominal aortic aneurysm sac healing and prevention of expansion) is a prospective, multicentre, randomised, open-label trial to determine safety and effectiveness of…
Aspirex achieves 78% two-year primary patency rate in P-MAX postmarket observational study
At the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany), Michael Lichtenberg (Arnsberg Vascular Clinic, Arnsberg, Germany) shared for the first time a 24-month update from the P-MAX study of the Aspirex (BD) endovascular thrombectomy system in the treatment…
The role of deep venous arterialization comes under scrutiny
“Every so often in vascular disease, disruptive technologies come along and the question really is, ‘Is this going to make a big impact on patient care?’” These were the words of CX Executive Board member Robert Hinchliffe, MBChB, clinical professor…
FastWave Medical announces successful 30-day first-in-human data on peripheral IVL technology
FastWave Medical has announced the 30-day results of its first-in-human (FIH) study using the company’s differentiated peripheral intravascular lithotripsy (IVL) technology. This was a prospective, single-arm study to assess the safety and feasibility of the FastWave IVL system in patients…
SVS approves FY 2024-2025 budget, sets priorities
The Society for Vascular Surgery (SVS) has unveiled its strategic plans for fiscal year 2024–2025. On April 2, the SVS Executive Board (EB) and Strategic Board of Directors (SBOD) approved the budget presented by SVS Treasurer Thomas Forbes, MD. The…
APDVS says goodbye to two long-term leaders during spring meeting
The 2024 Association of Program Directors in Vascular Surgery (APDVS) convened in Chicago April 5–6 for their annual spring meeting, which held the record for the highest-attended in APDVS history. APDVS 2024 covered important topics for vascular surgery program directors,…
SVS Foundation awards announced
The SVS Foundation has announced recipients for the 2023–2024 awards cycle. The slew of awardees is headed by the winner of the S.T. Yao Resident Research Award winner, Kevin D. Mangum, MD, an integrated vascular resident at the University of…
‘I’m a big fan of firsts’: Nationally renowned speaker on DEI set to headline new SVS keynote
Karith Foster, chief executive of Inversity Solutions, is set to headline the inaugural Society for Vascular Surgery (SVS) Keynote Speaker Series at the 2024 Vascular Annual Meeting (VAM 2024). It starts with a title. For Foster, her keynote begins with…
‘What if we could translate the most durable Dacron repair into a minimally invasive approach?’
Imagine a world in which the enduring Dacron graft, birthed by vascular pioneer Michael DeBakey, MD, some 70 years ago as an open repair for aortic aneurysms, could be performed minimally invasively with the sorts of gains associated with endovascular…